Stuart W Hicks
Overview
Explore the profile of Stuart W Hicks including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
589
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Scribner J, Hicks S, Sinkevicius K, Yoder N, Diedrich G, Brown J, et al.
Mol Cancer Ther
. 2022 May;
21(7):1047-1059.
PMID: 35511740
ADAM metallopeptidase domain 9 (ADAM9) is a member of the ADAM family of multifunctional, multidomain type 1 transmembrane proteins. ADAM9 is overexpressed in many cancers, including non-small cell lung, pancreatic,...
2.
Hicks S, Tarantelli C, Wilhem A, Gaudio E, Li M, Arribas A, et al.
Haematologica
. 2019 Feb;
104(8):1633-1639.
PMID: 30733273
Antibody-drug conjugates (ADC) are a novel way to deliver potent cytotoxic compounds to cells expressing a specific antigen. Four ADC targeting CD19, including SAR3419 (coltuximab ravtansine), have entered clinical development....
3.
Hicks S, Lai K, Gavrilescu L, Yi Y, Sikka S, Shah P, et al.
Neoplasia
. 2017 Jul;
19(9):661-671.
PMID: 28753442
Naratuximab emtansine (IMGN529) is an investigational antibody-drug conjugate consisting of a CD37-targeting antibody conjugated to the maytansine-derived microtuble disruptor, DM1. IMGN529 has shown promising preclinical and clinical activity in non-Hodgkin...
4.
Catcott K, McShea M, Bialucha C, Miller K, Hicks S, Saxena P, et al.
MAbs
. 2016 Jan;
8(3):513-23.
PMID: 26752675
Antibody-drug conjugates (ADCs) are of great interest as targeted cancer therapeutics. Preparation of ADCs for early stage screening is constrained by purification and biochemical analysis techniques that necessitate burdensome quantities...
5.
Wilmes G, Carey K, Hicks S, Russell H, Stevenson J, Kocjan P, et al.
MAbs
. 2014 Apr;
6(4):957-67.
PMID: 24758837
Antibody combination therapeutics (ACTs) are polyvalent biopharmaceuticals that are uniquely suited for the control of complex diseases, including antibiotic resistant infectious diseases, autoimmune disorders and cancers. However, ACTs also represent...
6.
Hicks S, Galan J
Nat Rev Microbiol
. 2013 Apr;
11(5):316-26.
PMID: 23588250
Several bacterial species have evolved specialized secretion systems to deliver bacterial effector proteins into eukaryotic cells. These effectors have the capacity to modulate host cell pathways in order to promote...
7.
Hicks S, Charron G, Hang H, Galan J
Cell Host Microbe
. 2011 Jul;
10(1):9-20.
PMID: 21767808
Several pathogenic bacteria utilize type III secretion systems (TTSS) to deliver into host cells bacterial virulence proteins with the capacity to modulate a variety of cellular pathways. Once delivered into...
8.
Zuckerman D, Hicks S, Charron G, Hang H, Machamer C
J Biol Chem
. 2011 Apr;
286(21):19014-23.
PMID: 21464135
S-Palmitoylation of G protein-coupled receptors (GPCRs) is a prevalent modification, contributing to the regulation of receptor function. Despite its importance, the palmitoylation status of the β(1)-adrenergic receptor, a GPCR critical...
9.
Hicks S, Galan J
Curr Opin Microbiol
. 2009 Dec;
13(1):41-6.
PMID: 20036613
Ubiquitinylation of proteins is a critical mechanism in regulating numerous eukaryotic cellular processes including cell cycle progression, inflammatory response, and vesicular trafficking. Given the importance of ubiquitinylation, it is not...
10.
Quezada C, Hicks S, Galan J, Stebbins C
Proc Natl Acad Sci U S A
. 2009 Mar;
106(12):4864-9.
PMID: 19273841
Processes as diverse as receptor binding and signaling, cytoskeletal dynamics, and programmed cell death are manipulated by mimics of host proteins encoded by pathogenic bacteria. We show here that the...